共 329 条
[1]
Al-Refaie WB(2011)Cancer trials versus the real world in the United States Ann Surg. 254 438-442
[2]
Vickers SM(2012)Methods in comparative effectiveness research J Clin Oncol Off J Am Soc Clin Oncol 30 4208-4214
[3]
Zhong W(2011)The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications Blood 117 5019-5032
[4]
Parsons H(2014)Determining disease prevalence from incidence and survival using simulation techniques Cancer Epidemiol 38 193-199
[5]
Rothenberger D(2013)Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles Lancet 381 1817-1826
[6]
Habermann EB(2014)Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 25 iii76-iii82
[7]
Armstrong K(2013)ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma Ann Oncol 24 857-877
[8]
Campo E(2014)Appropriate management of molecular subtypes of diffuse large B-cell lymphoma Oncol Williston Park N 28 326-334
[9]
Swerdlow SH(2006)Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants Cancer 106 2452-2458
[10]
Harris NL(2013)Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer 49 1374-1403